Infectivity of different HIV-1 strains may depend on which cell receptors they target

December 6, 2018, Public Library of Science
HIV-1 Virus. Credit: J Roberto Trujillo/Wikipedia

Distinct HIV-1 strains may differ in the nature of the CCR5 molecules to which they bind, affecting which cells they can infect and their ability to enter cells, according to a study published December 6 in the open-access journal PLOS Pathogens by Bernard Lagane of the Institut Pasteur and INSERM, and colleagues. As noted by the authors, the findings have implications for the development of HIV-1 entry inhibitors targeting CCR5.

CCR5 is a protein on the surface of white blood involved in regulating host immune responses against pathogens. It also serves as an anchor for certain of HIV-1 to infect , thereby contributing to the development of AIDS. CCR5 exists in different forms, but the mechanisms that govern this diversity and its consequences on functions of the receptor remain unclear. Because genetically diverse viral strains populate HIV-1 infected individuals, Lagane and colleagues examined whether divergent viruses differ in the nature of the CCR5 molecules they use, and if so, whether this accounts for differences in their biological properties.

The results provide positive answers to both of these questions. The researchers also identified CCR5 oligomerization—the formation of a molecular complex consisting of several CCR5 units—as a key process regulating the receptor conformational diversity, the extent to which HIV-1 can bind to target cells and the efficacy of viral entry. From a functional standpoint, the nature and quantity of the receptor populations used by HIV-1 strains regulate the type of cells they can infect and their ability to escape mechanisms that inhibit viral entry. According to the authors, this study represents a step toward understanding the mechanisms that regulate CCR5 diversity and its implications on viral biological properties, while opening new avenues for the development of drugs targeting CCR5.

"Divergent HIV-1 strains may differ in the nature of the CCR5 forms they use for entry into host cells," concludes Lagane. "This is likely to control the type of cells they can infect and ability to resist inhibition by CCR5 targeting, anti-HIV compounds."

Explore further: Genetic relic of the 'black death' may offer clues in treating liver disease

More information: Colin P, Zhou Z, Staropoli I, Garcia-Perez J, Gasser R, Armani-Tourret M, et al. (2018) CCR5 structural plasticity shapes HIV-1 phenotypic properties. PLoS Pathog 14(12): e1007432.

Related Stories

Genetic relic of the 'black death' may offer clues in treating liver disease

December 3, 2018
A gene mutation that is believed to have safeguarded some people in 14th century Europe from the bubonic plague today may be protecting HIV patients co-infected with hepatitis C from potentially fatal liver scarring, says ...

Gene-edited stem cells show promise against HIV in non-human primates

April 19, 2018
Gene editing of bone marrow stem cells in pigtail macaques infected with simian/human immunodeficiency virus (SHIV) significantly reduces the size of dormant "viral reservoirs" that pose a risk of reactivation. Christopher ...

New insight into role of cell protein in learning ability and AIDS-related dementia

January 17, 2017
Researchers from the University of California (UCLA) and Cardiff University have made a breakthrough in the understanding of AIDS-related dementia, discovering the role of a neuron protein which was also found to affect learning ...

HIV drug may slow down metastatic breast cancer

June 6, 2012
The HIV drugs known as CCR5 antagonists may also help prevent aggressive breast cancers from metastasizing, researchers from the Kimmel Cancer Center at Jefferson suggest in a preclinical study published in a recent issue ...

Recommended for you

RNA processing and antiviral immunity

December 14, 2018
The RIG-I like receptors (RLRs) are intracellular enzyme sentries that detect viral infection and initiate a first line of antiviral defense. The cellular molecules that activate RLRs in vivo are not clear.

Faster test for Ebola shows promising results in field trials

December 13, 2018
A team of researchers with members from the U.S., Senegal and Guinea, in cooperation with Becton, Dickinson and Company (BD), has developed a faster test for the Ebola virus than those currently in use. In their paper published ...

Drug targets for Ebola, Dengue, and Zika viruses found in lab study

December 13, 2018
No drugs are currently available to treat Ebola, Dengue, or Zika viruses, which infect millions of people every year and result in severe illness, birth defects, and even death. New research from the Gladstone Institutes ...

Urbanisation and air travel leading to growing risk of pandemic

December 13, 2018
Increased arrivals by air and urbanisation are the two main factors leading to a growing vulnerability to pandemics in our cities, a University of Sydney research team has found.

Researchers discover new interactions between Ebola virus and human proteins

December 13, 2018
Several new connections have been discovered between the proteins of the Ebola virus and human host cells, a finding that provides insight on ways to prevent the deadly Ebola virus from reproducing and could lead to novel ...

Faecal transplants, 'robotic guts' and the fight against deadly gut bugs

December 13, 2018
A simple compound found in our gut could help to stop dangerous bacteria behind severe, and sometimes fatal, hospital infections.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.